echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > 5 billion varieties! New recruits of rosuvastatin in Jingxin pharmaceutical

    5 billion varieties! New recruits of rosuvastatin in Jingxin pharmaceutical

    • Last Update: 2019-05-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medical network, May 16 -- on May 15, Beijing New Pharmaceutical Co., Ltd announced that it had received the registration approval document of rosuvastatin calcium dispersible tablets (specification: 10mg) approved and issued by the State Food and drug administration According to the data of minenet, in 2017, the sales volume of rosuvastatin tablets in public medical institutions in China was 5.019 billion yuan Rosuvastatin calcium dispersible tablet is a kind of drug for the treatment of hyperlipidemia It is suitable for the primary hypercholesterolemia (type IIA, including heterozygous familial hypercholesterolemia) or mixed type dyslipidemia (type IIB) which can not be properly controlled by diet control and other non drug treatment (such as exercise therapy, weight loss) Rosuvastatin calcium dispersible tablets disintegrated rapidly when exposed to water, especially for the elderly or patients with dysphagia, so as to improve the compliance of patients Sales of rosuvastatin tablets at the terminals of public medical institutions in China (unit: 10000 yuan) according to the data of minenet, the sales of rosuvastatin tablets at the terminals of public medical institutions in China in 2017 was 5.019 billion yuan AstraZeneca, the original research manufacturer, occupies 56.71% of the market share, while lunanbert pharmaceutical, Jingxin pharmaceutical and Nanjing Zhengda Tianqing pharmaceutical all account for more than 10% In recent years, the market share of risuvastatin calcium tablets in Jingxin pharmaceutical industry has been growing, from 8.88% in 2013 to 13.37% in 2017, while the market share of AstraZeneca dropped from 69.64% in 2013 to 56.71% in 2017 In 2017, Beijing New Pharmaceutical Co., Ltd said that the approval further enriched the company's statins series products and dosage forms, which is conducive to improving the market competitiveness of cardiovascular and cerebrovascular series products, and has a positive impact on the company's future business performance.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.